Sugi Predict

Sugi Predict / Compounds / SCHEMBL4081998

SCHEMBL4081998

SCHEMBL4081998

C[C@@H](C1CCCCC1)C(NC(=O)Nc1ccc2ccccc2c1)c1ccc(C(=O)NCCC(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCG P01275 8/20 0.46
▸ EPHX1 P07099 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTR1E P28566 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ S1PR3 Q99500 1/20 0.46
▸ EGLN2 Q96KS0 1/20 0.44
▸ EGLN1 Q9GZT9 1/20 0.44
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PYGL P06737 1/20 0.42
▸ GCGR P47871 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081990 1.00 GCG (0.46) GCGEPHX1MEN1KMT2ALMNA
SCHEMBL4085246 0.85 GCGR (0.47) GCGGCGR
SCHEMBL4086822 0.83 GCGR (0.56) EPHX1GCGRADCY6ADCY3ADCY9
SCHEMBL4095940 0.80 GCGR (0.51) GCGEPHX1GCGRADCY6ADCY3
SCHEMBL4081993 0.80 GCGR (0.49) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4081986 0.80 GCGR (0.49) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL9072778 0.77 GCGR (0.48) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4092388 0.73 CYP2D6 (0.51) GCGCYP2D6GCGR
SCHEMBL2650367 0.72 GCG (0.45) GCGGCGRNPC1RAB9A
SCHEMBL4087094 0.72 MCHR1 (0.48) GCGEPHX1GCGRADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCG 5/4885EPHX1 2751/4885MEN1 2079/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCG 5/4885EPHX1 2751/4885MEN1 2079/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCG 5/4885EPHX1 2751/4885MEN1 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.